AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 6 - (NewsRx.com & NewsRx.net) -- Priority Healthcare Corporation (Nasdaq: PHCC) announced that it is adjusting its sales guidance for the third quarter ending on October 2, 2004, due to the delays in shipment and the release of Fluvirin, its primary flu vaccine product, and the negative impact due to hurricanes Charley and Frances.
Specific to the delays in vaccine shipments, Chiron Corporation announced on August 26, 2004, its delay in releasing any Fluvirin until early October, after additional quality checks could be conducted.
The company is also adjusting earnings guidance down by $.01 to $.02 per share for the third quarter due to the lower sales guidance and start up costs related to its new agreement with Aetna.
Based on the above, third quarter sales guidance has been adjusted to $436 million to $446 million and earnings guidance has been adjusted to $.29 to $.30 per share.
Steve Cosler, Priority Healthcare president and CEO commented, "Although the change in our third quarter guidance is minimal, and ...